20
Participants
Start Date
November 30, 2016
Primary Completion Date
July 31, 2022
Study Completion Date
July 31, 2022
Vinorelbine
Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
Shanghai Children's Medical Center, Shanghai
Children's Cancer Group, China
NETWORK